FDA Alert: Intelence (etravirine)
Links shared publicly online about this topic.
- 1,792total visits
FDA Alert: Intelence (etravirine)
View full resource at drugs.com
Tags: HIV Medication, FDA, Intelence
Most Recently Shared on August 27, 2009 at 10:33 pm By:
FDA Alert - Tibotec and FDA Update Warnings for Intelence - http://bit.ly/RZkm0
FDA OKs label update for etravirine - - Drug Topics
drugtopics.modernmedicine.com — “FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on January 19, 2011 at 12:30 am By:
FDA OKs label update for etravirine: FDA has approved a label update to include a 200-mg formulation of etraviri... http://bit.ly/flcUHS
FDA OKs label update for etravirine - - Drug Topics
drugtopics.modernmedicine.com — “FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on January 17, 2011 at 6:02 pm By:
Drugs and Devices OW OW Health
FDA OKs label update for etravirine: FDA has approved a label update to include a 200-mg formulation of ... http://bit.ly/ehRGH2 #pharma
FDA OKs label update for etravirine - - Drug Topics
drugtopics.modernmedicine.com — “FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on January 17, 2011 at 4:44 pm By:
Drugs and Devices OW OW Health
FDA OKs label update for etravirine: FDA has approved a label update to include a 200-mg formulation of et... http://bit.ly/h7GRjW #drug
FDA Approves New Dosage Strength For INTELENCE(R)
medicalnewstoday.com — “The U.S. Food and Drug Administration(FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicate” View full resource at medicalnewstoday.com
Most Recently Shared on January 4, 2011 at 5:05 pm By:
MNT Drug Approvals Health News
FDA Approves New Dosage Strength For INTELENCE(R) http://mnt.to/3PBF #regulatory
FDA Approves New Dosage Strength for Intelence
drugs.com — “Intelence (etravirine) is used to treat HIV infection. Includes Intelence side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on January 4, 2011 at 4:10 am By:
Drugs and Devices OW OW Health
FDA Approves New Dosage Strength for Intelence: TITUSVILLE, N.J., Jan. 3, 2011 /PRNewswire/ -- The U.S. Fo... http://bit.ly/fCWTaJ #drug
Intelence 200mg dosage strength approved - ONA
oncologynurseadvisor.com — “The FDA has approved a 200mg dosage strength of Intelence (etravirine tablets, from Tibotec), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 in treatment-experienced adults with resistance to an NNRTI and other antiretroviral agents.” View full resource at oncologynurseadvisor.com
Most Recently Shared on January 3, 2011 at 3:32 pm By:
OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education
Intelence 200mg dosage strength approved http://goo.gl/fb/xiVQt
Intelence 200mg dosage strength approved - MPR
empr.com — “The FDA has approved a 200mg dosage strength of Intelence (etravirine tablets, from Tibotec), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 in treatment-experienced adults with resistance to an NNRTI and other antiretroviral agents.” View full resource at empr.com
Most Recently Shared on January 3, 2011 at 3:27 pm By:
MPR News: Intelence 200mg dosage strength approved: The FDA has approved a 200mg dosage strength of Intelence (e... http://bit.ly/gfbWgo
FDA approves 200 mg formulation of INTELENCE for HIV-1
news-medical.net — “The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.” View full resource at news-medical.net
Most Recently Shared on January 3, 2011 at 2:43 pm By:
FDA approves 200 mg formulation of INTELENCE for HIV-1: The U.S. Food and Drug Administration (FDA) approved a l... http://bit.ly/ifukgn
Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information - The Body
thebody.com — “FDA recently updated Intelence (etravirine) label to include drug-drug interaction information between etravirine and fluconazole, voriconazole, ...” View full resource at thebody.com
Most Recently Shared on March 15, 2010 at 1:01 pm By:
Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information http://bit.ly/cgGYeC #hiv #aids #etravirine
Intelence granted traditional approval by FDA for HIV - MPR
empr.com — “Tibotec announced that the FDA has granted traditional approval for Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use in treatment-experienced adults who are experiencing virologic failure with HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents.” View full resource at empr.com
Most Recently Shared on November 30, 2009 at 4:52 pm By:
MPR News: Intelence granted traditional approval by FDA for HIV: Tibotec announced that the FDA has granted traditi... http://bit.ly/4yJWcg
Medical News: FDA Warns of Increased Danger with HIV Drug - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA alerted healthcare professionals that the HIV medication etravirine (Intelence) may cause severe skin reactions, and the manufacturer has updated the drug's label accordingly.” View full resource at medpagetoday.com
Most Recently Shared on August 30, 2009 at 12:35 am By:
FDA Warns of Increased Danger with HIV Drug http://ow.ly/15MYnd
Severe skin reactions warning added to Intelence labeling - MPR
empr.com — “The FDA has notified healthcare professionals that the labeling for Intelence (etravirine tablets, from Tibotec) has been updated to include postmarketing reports of severe skin and hypersensitivity reactions.” View full resource at empr.com
Most Recently Shared on August 28, 2009 at 3:40 pm By:
MPR News: Severe skin reactions warning added to Intelence labeling: The FDA has notified healthcare pr.. http://bit.ly/1YZXFP
Advertisement
